Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
This page provides a historical news archive for Singular Genomics Systems, Inc., which previously traded on Nasdaq under the symbol OMIC. The company describes itself as a life science technology company developing next-generation sequencing (NGS) and multiomics technologies, including the G4® Sequencing Platform and the G4X™ Spatial Sequencer. Its news releases document product milestones, spatial biology data presentations, corporate transactions and capital markets developments.
Readers can review announcements about the G4 Sequencing Platform, which Singular Genomics characterizes as a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. News items also cover progress on the G4X Spatial Sequencer, described as a system under development that will apply the company’s proprietary sequencing technology as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue with spatial context.
The archive includes updates on spatial multiomics performance in FFPE tissues, 3D multi-omic reconstruction, Direct-Seq demonstrations for T- and B-cell receptor sequencing in tissue, and the company’s Spatial Technology Access Services program. In addition, corporate news covers events such as a 1-for-30 reverse stock split to address Nasdaq’s minimum bid price requirement, the receipt of acquisition proposals, the definitive merger agreement with an affiliate of Deerfield Management Company, L.P., and the closing of the Deerfield acquisition after stockholder approval.
Because Singular Genomics has stated that it now operates as a private company and has requested delisting from Nasdaq, the OMIC news feed serves as a record of its public-company history, technology development updates and key strategic decisions during its time as a listed issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced it will report its Q1 2023 financial results after market close on May 9, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
The company specializes in next-generation sequencing and multiomics technologies, with the G4 Sequencing Platform available commercially, enabling fast and accurate genomic sequencing. Additionally, the PX system is under development, focusing on in situ readouts for RNA and proteins in cells and tissues.
For investors interested in the conference call, a live and archived webcast can be accessed through the company’s investor portal.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported its fourth quarter and full-year results for 2022, marking a pivotal year with significant milestones. The company achieved its first revenue of $765,000, primarily from three instrument placements. Operating expenses rose to $22.5 million in Q4 2022, driven by increased headcount and infrastructure for the G4 launch. Despite a net loss of $21.1 million in Q4, the loss per share improved to $0.29 from $0.27 year-over-year. For the full year, revenue totaled $765,000, while the net loss decreased to $90.9 million, or $1.28 per share, compared to $2.10 in 2021. Cash reserves stood at $244.6 million.
Singular Genomics Systems (Nasdaq: OMIC) has announced its participation at Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023. The company's management will engage in a fireside chat at 8:10 a.m. PT / 11:10 a.m. ET. Interested investors can access a live and recorded webcast of this presentation through their investor relations website.
Singular Genomics is advancing life science technology with its G4 Sequencing Platform and developing the PX system, aiming to enhance research and clinical outcomes through next-generation sequencing and multiomics technologies.